[Effects of prostacyclin MM-706 on liver function restoration in dogs after severe hemorrhagic shock]. / Vplyv prostatsyklinu MM-706 na vidnovlennia funktsii pechinky u sobak pislia tiazhkoho hemorahichnoho shoku.

The new synthetic analogue of prostaglandin I2 (prostacyclin MM-706) influence on some hepatic function indexes was studied up in 7 dogs with an acute hepatic insufficiency caused by severe hemorrhagic shock. Rapid and steady normalization of indexes and the animals survival were promoted by intravenous infusion of MM-706 given in 300 ng/kg dose together with hemocorrector named lactoprotein given in 10 ml/kg dose (7,5 +/- 1,4) hours later. Possible action mechanisms of the MM-706 therapeutic efficacy are considered. Results of investigation performed constitute an experimental base of the MM-706 application in the complex treatment of an acute hepatic insufficiency of different genesis in the clinic.

[Contents of prostaglandins F2alpha, I2 (prostacyclin) and thromboxane A2 in the dog liver during development of hemorrhagic shock]. / Soderzhanie prostaglandinov F2alfa, I2 (prostatsiklina) i tromboksana A2 v pecheni sobak v dinamike razvitiia gemorragicheskogo shoka.

Contents of prostaglandins (PGs) F2 alpha, I2 and thromboxane (TH) A2 in the liver of 6 dogs has been studied in dynamics of hemorrhagic shock development. The results show that acute haemorrhage (31.9 +/- 1.6 ml/kg) stimulates the synthesis and release of all the eicosanoids studied. Nevertheless, in the progression of shock a significant difference was noticed between the high TXA2 and PGF2 alpha rates and comparatively lower rise of PGI2 production. The late stage of shock (201 +/- 44 minutes after haemorrhage) was characterized by a further rise in TXA2 and PGF2 alpha rates with simultaneous lowering of PGI2 as a result of vascular endothelium affection which is the main source for prostacyclin synthesis. In view of the antagonism of PGI2 to TXA2 and PGF2 alpha and its cytoprotective effects, the results of present investigation give the experimental background for using prostacyclin or its synthetic analogues in a complex therapy of acute liver failure in clinic.